03.22.23 -- Optimize Product Life Cycles With A Collaborative Partnership Model

Regular assessments of a partnership’s value in terms of supply chain, operational efficiency, data analysis, and more can optimize and extend the product life cycle. This need is particularly pressing for pharma companies operating in the generics or branded over-the-counter (OTC) spaces, since extending the product life cycle depends on lowering costs in response to competition-driven price pressure.

Topical products, whether prescription dermatological drugs or over-the-counter lotions, creams, or gels, present unique challenges in terms of development and manufacturing. When faced with the many challenges of producing a safe, cost-effective, high-quality topical product, many companies will seek the expertise and experience of a CDMO partner.

Understanding both the significant competitive advantages that fixed-dose combination (FDC) products can offer and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. Explore considerations for design, formulation, manufacturing, and analysis.